Moderna and Merck report sustained melanoma treatment benefits at 5 years

June 1, 2026 8:01 AM

Moderna Inc. (NASDAQ: MRNA) and Merck (NYSE: MRK) announced five-year follow-up data from their Phase 2b melanoma study showing sustained ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found